Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.

Neal D. Shore; Fred Saad; Egils Vjaters; David Olmos; Natasha Littleton; Anna Liu; Isabella Testa; Mindy Mo; Shankar Srinivasan; Kunhi Parambath Haresh

doi:10.1200/JCO.2025.43.5_suppl.151

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.

Neal D. Shore
, Fred Saad
, Egils Vjaters
, David Olmos
, Natasha Littleton
, Anna Liu
, Isabella Testa
, Mindy Mo
, Shankar Srinivasan
, Kunhi Parambath Haresh

Research output: Contribution to journal › Meeting Abstract › peer-review

1 Downloads (Pure)

Original language	English
Pages (from-to)	151
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	43
Issue number	5_SUPPL
DOIs	https://doi.org/10.1200/JCO.2025.43.5_suppl.151
Publication status	Published - 10 Feb 2025
Externally published	Yes
Event	2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium - San Francisco, United States Duration: 13 Feb 2005 → 15 Feb 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1200/JCO.2025.43.5_suppl.151

Darolutamide plus ADT in patients withFinal published version, 57 KB

Cite this

Shore, N. D., Saad, F., Vjaters, E., Olmos, D., Littleton, N., Liu, A., Testa, I., Mo, M., Srinivasan, S., & Haresh, K. P. (2025). Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial. Journal of Clinical Oncology, 43(5_SUPPL), 151. https://doi.org/10.1200/JCO.2025.43.5_suppl.151

@article{b6afa6a4355f450c9fa985609583de0c,

title = "Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.",

author = "Shore, \{Neal D.\} and Fred Saad and Egils Vjaters and David Olmos and Natasha Littleton and Anna Liu and Isabella Testa and Mindy Mo and Shankar Srinivasan and Haresh, \{Kunhi Parambath\}",

year = "2025",

month = feb,

day = "10",

doi = "10.1200/JCO.2025.43.5\_suppl.151",

language = "English",

volume = "43",

pages = "151",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "5\_SUPPL",

note = "2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, ASCO GU ; Conference date: 13-02-2005 Through 15-02-2025",

}

Shore, ND, Saad, F, Vjaters, E, Olmos, D, Littleton, N, Liu, A, Testa, I, Mo, M, Srinivasan, S & Haresh, KP 2025, 'Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.', Journal of Clinical Oncology, vol. 43, no. 5_SUPPL, pp. 151. https://doi.org/10.1200/JCO.2025.43.5_suppl.151

TY - JOUR

T1 - Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume

T2 - 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium

AU - Shore, Neal D.

AU - Saad, Fred

AU - Vjaters, Egils

AU - Olmos, David

AU - Littleton, Natasha

AU - Liu, Anna

AU - Testa, Isabella

AU - Mo, Mindy

AU - Srinivasan, Shankar

AU - Haresh, Kunhi Parambath

PY - 2025/2/10

Y1 - 2025/2/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:001454759900029&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1200/JCO.2025.43.5_suppl.151

DO - 10.1200/JCO.2025.43.5_suppl.151

M3 - Meeting Abstract

SN - 0732-183X

VL - 43

SP - 151

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5_SUPPL

Y2 - 13 February 2005 through 15 February 2025

ER -

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this